When the Product Name Is Itself the Disease Claim

which parts of a page can create a disease claim without any text?

Five of the ten disease-claim triggers under 21 CFR 101.93(g)(2) don't need a single word of body copy. The rule that defines a disease claim — the sentence that turns a dietary supplement into an unapproved drug — lists a product's name, its imagery, and its ingredient citations as standalone evidence, sitting right alongside the sentences an advertiser actually writes. A structure/function claim, the lawful description of a nutrient's role, only survives if none of these ten triggers fire.

A picture can do the whole job.

Subparagraph (iv) alone breaks into five separate routes — we counted them against the text at eCFR — running from (A) the product's name through formulation statements, citations, and the literal word "disease," ending at (E) pictures, vignettes, symbols, or other means. FDA doesn't require all five to fire together; one is enough. A page built entirely from clean, disease-free sentences can still fail on the strength of its own name or its hero image, and a review that only reads the copy is reading half the page.

how did fda use a product name as evidence in the bergamet letter?

FDA treated the product's own name as the first piece of evidence. In its November 2022 warning letter to BergaMet North America, FDA cited the name "Cholesterol Command" alongside the express claim on the label: "BergaMet Cholesterol Command is clinically proven to improve cholesterol levels. It reduces LDL." The name did legal work the sentence didn't need to do twice — under 101.93(g)(2)(iv)(A), the name alone would have been enough to convert the product into an unapproved new drug, regardless of how the rest of the label read.

FDA then reached past the label entirely. The letter quoted a money-back guarantee promising a refund "if they do not improve your LDL levels" — a guarantee is itself a claim — and a third-party Walmart listing describing "a bergamot supplement for high cholesterol," evidence the brand never wrote. It also cited a customer's Facebook comment the brand had liked: "I have had amazing results with this supplement it brought down all my levels out of the red and into a very healthy range." The same logic applies wherever a heart icon or a lab graphic implies disease treatment instead of stating it.

The name never needed a partner claim to fail.

what makes before-and-after imagery read as an obesity claim?

A before-and-after photo reads as an obesity claim because 21 CFR 101.93(g)(2)(iv)(E) names imagery as a standalone trigger — the picture carries the claim whether or not any caption names a disease. FTC's own Gut Check guidance backs this from the substantiation side: "substantial weight loss can be suggested by reference to dress size, inches, or body fat," no number required. Whether before-and-after photos are allowed in an ad at all depends heavily on which platform is running it, and the platform rule and the FDA rule are not the same test.

Most media buyers treat platform approval as the finish line — if a platform clears the creative, the thinking goes, the compliance work is done. That's backwards. Meta's own policy permits before-and-after transformation imagery for general cosmetic products targeted to adults, which tells you nothing about whether FDA would read the same photo as disease evidence on a weight-loss supplement. Platform review checks platform policy; it has no mechanism for applying 101.93(g)(2), and an ad that clears creative review can still become the label evidence in a federal warning letter months later.

Platform approval is not a legal opinion.

do medical icons, lab coats and stethoscopes carry the same risk?

Yes, medical icons and lab coats carry the same evidentiary weight as photographs, because FDA and FTC both read imagery for what it implies rather than what it labels. FTC's Health Products Compliance Guidance makes the point with a hypothetical built to close exactly this loophole: an ad for a joint supplement called "Arthricure" that claims only to maintain "joint health and mobility" still conveys a disease claim once it runs a before photo of an elderly woman using a walker.

The companion example, "Cold Away," makes the same point from the opposite direction — sneezing and coughing imagery plus winter nose-and-throat copy adds up to a cold-prevention claim, and FTC states the text alone would already convey it without the pictures. A stethoscope graphic, a clipboard-and-checklist icon, or a lab-coat photo function the same way: none of them names a disease, and none of them needs to. Treat medical iconography as a claim, not decoration, before it ends up quoted back to you in a warning letter.

can compliant body copy rescue a non-compliant name?

No — compliant body copy cannot rescue a non-compliant name, because the DSHEA disclaimer, required under the 1994 supplement law, only protects claims that were lawful to begin with. FTC's guidance describes an app that claimed to treat acne while carrying a disclaimer that it was "for entertainment purposes only," and concluded the disclaimer was "directly contradictory and ineffective to negate the acne treatment claim." The same failure applies to a name.

FDA's own rule text backs this reading directly: 21 CFR 101.93(f) states that a product bearing a disease claim is regulated as a drug unless it qualifies for an authorized health claim — the disclaimer isn't listed as an exit. If your product is named after the condition it treats, no amount of careful body copy underneath it changes what the name already said. Fix the name, or accept that you're marketing a drug without an approval.

The disclaimer covers lawful claims; it doesn't repair unlawful ones.

what does this mean for white-label and rebranded offers?

White-label and private-label offers inherit the full risk of whatever name they ship under, because FDA's analysis runs on the name printed on the bottle, not on who is selling it. A contract manufacturer typically owns the formula and the name under a private-label arrangement unless the agreement says otherwise, which means the brand licensing a "Cholesterol Command"-style name doesn't necessarily control it. We could not verify how often manufacturers reuse a disease-implying master name across multiple private-label clients — no public database tracks SKU-to-brand relationships. Checking a manufacturer's catalog against FDA's warning letter list before licensing a name would settle it.

The same pattern shows up outside cholesterol and weight loss. A bulging-leg before/after photo functions as the disease claim on its own in vein-health advertising, the same way a name does in supplements — and a white-label vein SKU sold under five different storefront brands carries that imagery risk five times over, not once. Ask what the master SKU's name and photo library already imply before you rebrand it.

Rebranding the label doesn't rebrand the risk.

how should creative be reviewed when the copy passes but the visuals do not?

Review the name, the imagery and the body copy as three separate line items, because 21 CFR 101.93(g)(2) evaluates each one independently and a pass on the sentences tells you nothing about the picture above them. A checklist built only for language — banned words, disease terms, comparative drug claims — will wave through a photo, a guarantee, or a product name that fails on its own. Build the review around the ten triggers, not around the paragraph.

We checked the fact pattern that actually got BergaMet North America cited in FDA's November 2022 letter, and the body copy was not where the case broke. The name did the damage first, the money-back guarantee did it a second time by promising a refund tied to LDL improvement, and a third-party retailer's own product description did it a third time by describing the item as a cholesterol product FDA never saw the brand write. Three separate failures stacked on top of language that, read in isolation, looked like an ordinary structure/function claim — a copy-only review would have passed all three and missed the letter FDA actually sent.

We changed our mind about where testimonial risk lives after reading that letter. We had treated a customer's words as the advertiser's problem only once quoted inside paid creative — the BergaMet letter counted a Facebook like on a customer's comment as an endorsement the brand made itself, pulling organic community management into the same review that covers the ad account. If your team likes or replies to comments claiming a cholesterol drop or a stopped prescription, that reply is now part of your claims file.

Quick decision checklist

Use this page as a decision aid, not a generic blog post. The practical question is whether the reader needs faster evidence about what is already working in VSL-driven direct response, especially across nutra, supplements, GLP-1, weight loss, blood sugar, and adjacent high-intent health markets.

Daily Intel Service is most relevant when the next decision depends on active market examples: which hook to test, which claim style is risky, which funnel structure is common, which language market is moving, and whether a competitor's creative is likely early, scaling, or already saturated.

• Start with the TL;DR if you need the direct answer.
• Use the table to compare trade-offs quickly.
• Use the FAQ for answer-engine-ready summaries.
• Use the CTA when the decision requires live VSL and ad examples instead of theory.

Daily Intel's coverage advantage

Daily Intel Service is positioned around category-leading variety and actionability: one of the broadest direct-response catalogs of VSLs and ad creatives across blackhat, greyhat, and whitehat advertising patterns, with enough context to understand what the advertiser is doing beyond the visible creative. The practical difference is that members are not just seeing a screenshot; they are seeing the VSL, the ad, the funnel path, the transcript, the UTM context, and the research notes that turn the asset into a decision.

This matters because direct-response affiliates do not operate in one clean category. A weight-loss campaign may use a whitehat compliance ad, a greyhat pre-lander, a more aggressive VSL, and a checkout path designed around upsells and recovery. A useful intelligence platform needs to capture that spectrum instead of pretending every winning campaign looks like a public brand ad.

Blackhat, whitehat, and multilingual signal coverage

Daily Intel tracks patterns across both blackhat-style and whitehat-style campaigns so operators can understand the market without blindly copying risk. Whitehat examples help with durability and compliance review; blackhat and greyhat examples reveal pressure points, hooks, mechanisms, and funnel structures that may be driving spend but require careful adaptation before use.

The catalog is also built for global operators, with VSL and ad references spanning 14+ languages and different local idioms. That is a key advantage for Brazilian, LATAM, European, MENA, Indian, and non-native English affiliates who need to see how the same market desire is translated across cultures instead of only studying US English ads.

How to use the intelligence responsibly

The goal is modeling, not copying. Use Daily Intel to understand structure: hook, mechanism, proof, claim intensity, funnel depth, offer economics, and saturation stage. Then build original creative, review claims, and adapt the angle to the traffic source, country, language, and compliance requirements of the campaign.

A strong workflow compares multiple examples before acting. If the same mechanism appears across several languages, several advertisers, and several funnel variants, it may be a durable market signal. If the example appears only once or depends on an aggressive claim, treat it as a research clue rather than a campaign template.

• Model structure, not protected creative assets.
• Separate whitehat durability from blackhat persuasion pressure.
• Compare US English examples against LATAM, European, and other language variants.
• Use transcripts and funnel notes to build original briefs.
• Keep compliance review separate from market research.

Methodology and source context

Daily Intel pages are written from a research workflow that reviews active VSLs, Meta ad creatives, transcripts, UTMs, funnel paths, checkout steps, upsells, recovery sequences, and compliance-sensitive claim patterns. The goal is to explain observable market behavior, not to provide legal, medical, or platform policy advice.

For external context, readers should compare advertising and research decisions against authoritative primary references such as FTC health claims guidance, Meta advertising standards, and Meta Ad Library. Daily Intel adds the proprietary direct-response layer: blackhat, greyhat, and whitehat campaign pattern comparison across VSL-heavy niches and 14+ language markets.

For deeper evaluation, continue through Nutra niche intelligence directory, NAD+ Supplement Offers: The Longevity Ad Gold Rush, Natural Ozempic Alternative Ads: Inside the 2026 Trend, Tinnitus Supplement Ads: What Still Works After Cortexi, Sleep Supplement Ads: Winning Angles Beyond Melatonin, and GLP-1 affiliate marketing intelligence. These related Daily Intel pages connect this topic to the relevant methodology, pricing, trust context, comparison path, or niche workflow.